Russian biotechnological drugs impress interest of the global pharmaceutical community

26 October 2018

GMP News

Madrid became the world capital of the pharmaceutical industry for three days, from 9th to 11th October. The city hosted CPhI Worldwide 2018, the largest international pharmaceutical exhibition, where the leading Russian pharmaceutical companies presented their products under the aegis of the Ministry of Industry and Trade of the Russian Federation.

CPhI Worldwide is the whole industry marker as it is the key platform to unite global players. Russia has long proved itself to be one of them. Recently, it has become even more evident in the sphere of biotechnology, in particular, in orphan recombinants, or, as they are also known, genetically engineered drugs (orphan drugs are drugs used for treating rare diseases).

Over ten manufacturing companies represented Russia at the event this year. Among them, GENERIUM biopharmaceutical enterprise deserves a special mention. The Company portfolio includes unique products extremely complex to develop and produce. They are designed for the treatment of rare diseases, cardiovascular disorders, and tuberculosis detection.

GENERIUM met its foreign partners interested in acquiring Russian pharmaceutical products. One of such partners is the Swiss company Stragen.

Antoine Tétard, General Manager for Business Development at Stragen:

“We were surprised when we first learned about GENERIUM; it’s the only manufacturer in the world to produce three blood coagulation factors for the treatment of all hemophilia types. Their innovative skin test Diaskintest, which is intended for tuberculosis detection, is currently undergoing pre-qualification in the World Health Organization (WHO). As for the prospective portfolio of the Company, we have not seen anything similar in terms of orphan diseases in any Company that took part in the event.”

Prof. Dmitriy KudlayGeneral Director of JSC GENERIUM:

“Business relationships with our partners from Europe, Middle East, Asia, South and Central America, show that Russia holds a leading position in the sphere of treatment of rare diseases, which lately have become a heavy burden for the state. No country in the world is known to have a similar product range. This is due to the right approach at the state level and high professional expertise of Russian scientists.”

New biosimilars of the Company raised special interest in the foreign pharmaceutical community; they are in preparation for approval and promise to become genuine bestsellers. These include drugs for the treatment of paroxysmal nocturnal hemoglobinuriaGaucher’s disease, and cystic fibrosis.

CPhI Worldwide 2018 exhibition, which gathered representatives of 153 countries and over 45,000 participants at one site, is a unique opportunity to share one’s achievements with the world and establish cooperation with companies from distant countries.

Source

Print

Shareholders

Read more

Pipeline

Read more

Media Center

Read more